Synthetic Lethality Drug Market is expected to reach USD 4.31 billion by 2031

Synthetic Lethality Drug Market Trends & Forecast

According to a research study published by Knowledge Sourcing Intelligence (KSI), the synthetic lethality drug market will expand from USD 3.06 billion in 2026 to USD 4.31 billion in 2031 at a CAGR of 7.1% during the forecast period.

Synthetic Lethality Drug Market focuses on commercialization and development of therapies that exploit genetic interactions within cancer cells while also enabling selective tumor destruction that spares normal tissues. Synthetic lethality occurs when the simultaneous destruction of two genes results in the death of a cell, whereas disruption of either gene alone remains lethal. This particular concept is important as it has gained substantial attention in oncology, particularly with the success of PARP inhibitors in patients harboring BRCA mutations.

There are several factors which are enabling researchers to identify novel synthetic lethal gene pairs across multiple cancer indications, such as advancements in genomic profiling technologies, along with large-scale CRISPR screening platforms and bioinformatics tools.

Request a free sample copy or view the report summary: Synthetic Lethality Drug Market Report

Synthetic Lethality Drug Market Report Highlights

• Advances in CRISPR gene editing technologies as well as functional genomics platforms are accelerating the growth of novel synthetic lethal targets.

• The increasing adoption of precision oncology approaches is furthermore driving the demand for synthetic-lethal-based therapeutics across different cancer indications.

• Strategic partnerships among pharmaceutical companies, research firms, and biotechnology firms are supporting innovation and expanding clinical development pipelines.

Synthetic Lethality Drug Market Growth Drivers and Restraints

Growth Drivers:

• The increasing incidence of cancers associated with BRCA1, BRCA2, ATM, PALB2, and other DNA damage repair gene mutations is fueling demand for targeted therapies based on synthetic lethality mechanisms. These therapies offer improved efficacy and reduced toxicity compared to conventional treatment approaches

• Rapid progress in biomarker identification, next-generation sequencing and computational biology are factors which are enabling the discovery of new synthetic lethal interactions. These are the new developments which are efficient in supporting drug development efforts while also expanding therapeutic opportunities across various cancer types.

Restraints:

• The discovery of clinically relevant synthetic lethal gene interactions is one of the major strains as it remains scientifically challenging and resource intensive. Additionally, tumor heterogeneity, variability in patient genetic profiles, and resistant mechanisms can also limit treatment effectiveness while delaying drug development timelines.

Synthetic Lethality Drug Market Growth Key Development

• May 2026: Artios Pharma Limited, which is regarded as a clinical-stage biopharmaceutical company, announced the dosing of its first patient in a randomized Phase 2 clinical trial.

• February 2026 – Artios Pharma Limited was granted the U.S. Food and Drug Administration (FDA) Fast Track designation to its potentially first-in-class DNA polymerase theta inhibitor.

• July 2025- Repare Therapeutics Inc., which is regarded as a clinical-stage precision oncology company, announced that it had entered into an exclusive worldwide licensing agreement with Debiopharm International S.A., which is regarded to be a privately owned, Swiss-based biopharmaceutical company.

Synthetic Lethality Drug Market Growth Segmentation

Knowledge Sourcing Intelligence has segmented the Synthetic Lethality Drug Market Growth based on mechanism of action, drug modality, indication, end-user, and region:

Synthetic Lethality Drug Market Growth, By Mechanism of Action

• PARP Inhibitors

• ATR Inhibitors

• WEE1 Inhibitors

• DNA-PK Inhibitors

• Emerging Targets

Synthetic Lethality Drug Market Growth By Drug Modality

• Small Molecules

• Biologics

• RNA-Based Therapies

• Cell & Gene Therapy

Synthetic Lethality Drug Market Growth, By Indication

• Ovarian Cancer

• Breast Cancer

• Prostate Cancer

• Lung Cancer

• Pancreatic Cancer

• Others

Synthetic Lethality Drug Market Growth, By End-User

• Hospitals

• Specialty Cancer Centers

• Research Institutes

Synthetic Lethality Drug Market Growth By Region

• North America

  • USA

  • Canada

  • Mexico

• Europe

  • United Kingdom

  • Germany

  • France

  • Italy

  • Spain

  • Others

• Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Australia

  • Thailand

  • Others

• South America

  • Brazil

  • Argentina

  • Others

• Middle East and Africa (MEA)

  • Saudi Arabia

  • UAE

  • Others

Synthetic Lethality Drug Market Growth Key Players

• AstraZeneca

• Merck & Co., Inc.

• GlaxoSmithKline Plc

• Repare Therapeutics Inc.

• IDEAYA Biosciences, Inc.

• Artios Pharma Ltd

• Zentalis Pharmaceuticals, Inc

• Merck KGaA

• Debiopharm Group

• Pfizer Inc.